HRS/EHRA/APHRS/LAHRS/ACC/AHA Worldwide Practice Update for Telehealth and Arrhythmia Monitoring During and after a Pandemic
Niraj Varma,Nassir F. Marrouche,Luis Aguinaga,Christine M. Albert,Elena Arbelo,Jong‐Il Choi,Mina K. Chung,Giulio Conte,Lilas Dagher,Laurence M. Epstein,Hamid Ghanbari,Janet K. Han,Hein Heidbüchel,He Huang,Dhanunjaya Lakkireddy,Tachapong Ngarmukos,Andrea M. Russo,Eduardo Saad,Luis Carlos Morales,Kristin E. Sandau,Arun Raghav Mahankali Sridhar,Eric C. Stecker,Paul A. Heidenreich
DOI: https://doi.org/10.1016/j.hrthm.2020.06.010
IF: 6.779
2020-01-01
Heart Rhythm
Abstract:1.Need for digital health during the COVID-19 pandemic 22.Monitoring strategies during a pandemic: Here to stay 33.Therapy for COVID-19 and potential electrical effects 74.The future: Digital medicine catalyzed by the pandemic 9References 10 Coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), started in the city of Wuhan in late 2019. Within a few months, the disease spread toward all parts of the world and was declared a pandemic on March 11, 2020. The current health care dilemma worldwide is how to sustain the capacity for quality services not only for those suffering from COVID-19 but also for non-COVID-19 patients, all while protecting physicians, nurses, and other allied health care workers. The pandemic poses challenges to electrophysiologists at several levels. Hospitalized COVID-19-positive patients may have preexisting arrhythmias, develop new arrhythmias, or be placed at increased arrhythmic risk from therapies for COVID-19. Cardiac arrhythmia incidence in hospitalized patients has been documented in a few published studies, with reported rates of 7.9%1Goyal P. Choi J.J. Pinheiro L.C. et al.Clinical characteristics of Covid-19 in New York City.N Engl J Med. 2020; 382: 2372-2374Crossref PubMed Scopus (1524) Google Scholar and 16.7%2Wang D. Hu B. Hu C. et al.Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China.JAMA. 2020; 323: 1061-1069Crossref PubMed Scopus (15459) Google Scholar in hospitals in New York City and Wuhan, respectively, and up to 44%2Wang D. Hu B. Hu C. et al.Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China.JAMA. 2020; 323: 1061-1069Crossref PubMed Scopus (15459) Google Scholar in patients requiring intensive care. Life-threatening arrhythmias (ventricular tachycardia [VT]/ventricular fibrillation [VF]) can occur in up to 6% of hospitalized patients with COVID-19 infection.3Guo T. Fan Y. Chen M. et al.Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19).JAMA Cardiol. 2020; 5: 811-818Crossref PubMed Scopus (2703) Google Scholar There have also been several case reports of atrioventricular block in hospitalized patients, which is otherwise rarely described during viral illness.4Azarkish M. Laleh Far V. Eslami M. Mollazadeh R. Transient complete heart block in a patient with critical COVID-19.Eur Heart J. 2020; 41: 2131Crossref PubMed Scopus (58) Google Scholar,5Noll A, William A, Varma N. A young woman presenting with a viral prodrome, palpitations, dizziness, and heart block. JAMA Cardiol. In press.Google Scholar Although the residual left ventricular dysfunction and arrhythmic risk are currently unknown, preliminary pathophysiological,6Kochi A.N. Tagliari A.P. Forleo G.B. Fassini G.M. Tondo C. Cardiac and arrhythmic complications in patients with COVID-19.J Cardiovasc Electrophysiol. 2020; 31: 1003-1008Crossref PubMed Scopus (405) Google Scholar histological,7Yao X.H. Li T.Y. He Z.C. et al.A pathological report of three COVID-19 cases by minimal invasive autopsies [in Chinese].Zhonghua Bing Li Xue Za Zhi. 2020; 49: 411-417PubMed Google Scholar and imaging8Inciardi R.M. Lupi L. Zaccone G. et al.Cardiac involvement in a patient with coronavirus disease 2019 (COVID-19).JAMA Cardiol. 2020; 5: 819-824Crossref PubMed Scopus (1250) Google Scholar data suggest that SARS-CoV-2 infection holds the potential to induce durable myocardial changes predisposing to arrhythmias or heart failure. Electrocardiographic monitoring and inpatient monitoring services may become necessary but face the potential hurdles of limited telemetry wards, contamination of equipment and infection in health care personnel, and shortage of personal protective equipment.9Sapp J.L. Alqarawi W. MacIntyre C.J. et al.Guidance on minimizing risk of drug-induced ventricular arrhythmia during treatment of COVID-19: a statement from the Canadian Heart Rhythm Society.Can J Cardiol. 2020; 36: 948-951Abstract Full Text Full Text PDF PubMed Scopus (94) Google Scholar,10Udwadia Z.F. Raju R.S. How to protect the protectors: 10 lessons to learn for doctors fighting the COVID-19 coronavirus.Med J Armed Forces India. 2020; 76: 128-131Crossref PubMed Scopus (32) Google Scholar In parallel, there is a continued responsibility to maintain care of COVID-19-negative patients with arrhythmias. These pressures have led to inventive utilization and adaptation of existing telemedicine technologies as alternative options. This document discusses how digital health may facilitate electrophysiology practice for patients with arrhythmia, whether hospitalized for COVID-19 or not. The representation of authors from some of the most severely affected countries, such as China, Spain, Italy, and the United States, is a tribute from our worldwide community to those colleagues who have worked on the front lines of the pandemic. In light of the current pandemic, monitoring strategies should focus on selecting high-risk patients in need of close surveillance and using alternative remote recording devices to preserve personal protective equipment and protect health care workers from potential contagious harm. For inpatient monitoring, telemetry is reasonable when there is concern for clinical deterioration (as may be indicated by acute illness, vital signs, or sinus tachycardia), or in patients with cardiovascular risk factors and/or receiving essential QT-prolonging medications. Telemetry is generally not necessary for persons under investigation without concern for arrhythmias or clinical deterioration and for those not receiving QT-prolonging drug therapy. In situations in which a hospital's existing telemetry capacity has been exceeded by patient numbers or when conventional telemetry monitoring is not feasible, such as off-site or nontraditional hospital units, mobile devices may be used, for example, mobile cardiac outpatient telemetry (MCT), as an adjunctive approach to support inpatient care.11Gabriels J. Saleh M. Chang D. Epstein L.M. Inpatient use of mobile continuous telemetry for COVID-19 patients treated with hydroxychloroquine and azithromycin.HeartRhythm Case Rep. 2020; 6: 241-243Abstract Full Text Full Text PDF PubMed Scopus (30) Google Scholar, 12Steinberg J.S. Varma N. Cygankiewicz I. et al.2017 ISHNE-HRS expert consensus statement on ambulatory ECG and external cardiac monitoring/telemetry.Heart Rhythm. 2017; 14: e55-e96Abstract Full Text Full Text PDF PubMed Scopus (186) Google Scholar, 13Garabelli P. Stavrakis S. Albert M. et al.Comparison of QT interval readings in normal sinus rhythm between a smartphone heart monitor and a 12-lead ECG for healthy volunteers and inpatients receiving sotalol or dofetilide.J Cardiovasc Electrophysiol. 2016; 27: 827-832Crossref PubMed Scopus (79) Google Scholar, 14Castelletti S. Dagradi F. Goulene K. et al.A wearable remote monitoring system for the identification of subjects with a prolonged QT interval or at risk for drug-induced long QT syndrome.Int J Cardiol. 2018; 266: 89-94Abstract Full Text Full Text PDF PubMed Scopus (41) Google Scholar, 15Gropler M.R.F. Dalal A.S. Van Hare G.F. Silva J.N.A. Can smartphone wireless ECGs be used to accurately assess ECG intervals in pediatrics? A comparison of mobile health monitoring to standard 12-lead ECG.PLoS One. 2018; 13e0204403Crossref PubMed Scopus (55) Google Scholar The majority of MCT devices can provide continuous arrhythmia monitoring using a single-lead electrocardiogram (ECG) and allow for real-time and offline analysis of long-term ECG data. Telemetry can be extended using patch monitoring.16US Food & Drug AdministrationVitalConnect, Inc. VitalPatch: letter of authorization (April 26, 2020).https://www.fda.gov/media/137397/downloadDate accessed: May 15, 2020Google Scholar,17VitalConnect. COVID-19.https://vitalconnect.com/covid-19-remote-patient-monitoringDate accessed: May 15, 2020Google Scholar Smartphone ECG monitors are wireless and have also been utilized during the current pandemic. Information is limited, however, on how parameters such as QTc measured on a single- (or limited number) lead ECG can reliably substitute for 12-lead ECG information.18Rimmer L.K. Rimmer J.D. Comparison of 2 methods of measuring the QT interval.Am J Crit Care. 1998; 7: 346-354Crossref PubMed Scopus (10) Google Scholar,19Rimmer L.K. Bedside monitoring of the QT interval.Am J Crit Care. 1998; 7: 183-189Crossref PubMed Scopus (7) Google Scholar In 1 study, QT was underestimated by the smartphone single-lead ECG.20Koltowski L, Balsam P, Glłowczynska R, et al. Kardia Mobile applicability in clinical practice: a comparison of Kardia Mobile and standard 12-lead electrocardiogram records in 100 consecutive patients of a tertiary cardiovascular care center [published online ahead of print January 15, 2019]. Cardiol J. https://doi.org/10.5603/CJ.a2019.0001.Google Scholar The principles of remote patient management, crossing geographic, social, and cultural barriers, can be extended to outpatient care and are important to maintain continuity of care for non-COVID-19 patients.21Ohannessian R. Telemedicine: potential applications in epidemic situations.Eur Res Telemed. 2015; 4: 95-98Crossref Scopus (94) Google Scholar, 22Hollander J.E. Carr B.G. Virtually perfect? Telemedicine for Covid-19.N Engl J Med. 2020; 382: 1679-1681Crossref PubMed Scopus (1939) Google Scholar, 23Liu S. Yang L. Zhang C. et al.Online mental health services in China during the COVID-19 outbreak.Lancet Psychiatry. 2020; 7: e17-e18Abstract Full Text Full Text PDF PubMed Scopus (1223) Google Scholar Virtual clinics move far beyond simple telephone contacts by integrating information from photos, videos, mobile heart rhythm and mobile health devices recording ECG, and remote cardiovascular implantable electronic device (CIED) interrogations.24Varma N. Ricci R.P. Telemedicine and cardiac implants: what is the benefit?.Eur Heart J. 2013; 34: 1885-1895Crossref PubMed Scopus (86) Google Scholar A variety of platforms have been developed and used specifically to provide telehealth to patients via video teleconferencing25NHSX. Information governance.https://www.nhsx.nhs.uk/covid-19-response/data-and-information-governance/information-governanceDate accessed: May 15, 2020Google Scholar,26NHS DigitalApproved video consultation systems.https://digital.nhs.uk/services/future-gp-it-systems-and-services/approved-econsultation-systemsDate accessed: May 15, 2020Google Scholar (Table 1). Most health care centers have expanded use of telemedicine, with some reporting 100% transformation of in-person clinic visits to telemedicine-based visits in order to maintain care for non-COVID-19 patients, thus obviating their need to come to the hospital or clinic. This supplements social distancing measures and reduces the risk of transmission, especially for the older and more vulnerable populations. It also becomes a measure to control intake into emergency rooms and outpatient facilities and to permit rapid access when necessary to subspecialists.Table 1Examples of commonly used platforms for telehealth25NHSX. Information governance.https://www.nhsx.nhs.uk/covid-19-response/data-and-information-governance/information-governanceDate accessed: May 15, 2020Google Scholar, 26NHS DigitalApproved video consultation systems.https://digital.nhs.uk/services/future-gp-it-systems-and-services/approved-econsultation-systemsDate accessed: May 15, 2020Google Scholar, 27National Health ServiceProcurement of pre-approved suppliers of online and video consultation systems for GP practices to support COVID-19.https://www.england.nhs.uk/coronavirus/wp-content/uploads/sites/52/2020/03/C0079-Suppliers-of-online-and-video-consultations.pdfDate accessed: April 29, 2020Google ScholarPlatformWebsiteHIPAA- or PHI-secure telehealth platformaccuRx∗United Kingdom.https://www.accurx.comAMD Global Telemedicine†Global.https://www.amdtelemedicine.com/telemedicine-products/Working-Clinic-Telemedicine.htmlAmerican Well‡United States.https://business.amwell.com/solution-overviewAttend Anywhere∗United Kingdom.https://www.attendanywhere.comBlueJeans for Healthcare‡United States.https://www.bluejeans.com/use-cases/healthcareCare Connect by KRY/LIVI§Europe.https://www.kry.careCaregility‡United States.https://caregility.com/uhe-applicationsCisco Webex†Global.https://www.webex.com/webexremotehealth.htmlClickDoc§Europe.https://www.cgm.com/be/index.fr.jspConexa Saúde¶South America—Brazil.https://www.conexasaude.com.brDocobo∗United Kingdom.https://www.docobo.co.ukDoctena§Europe.https://secure.doctena.comDoctorlink∗United Kingdom.https://www.doctorlink.com/video-consultationDoximity‡United States.https://www.doximity.comDoxy.me‡United States.https://doxy.meEMIS Health Video Consult∗United Kingdom.https://www.emishealth.com/products/video-consultationExprivia§Europe.https://www.exprivia.itFaceTalk§Europe.https://facetalk.nlGoogle G Suite†Global.https://gsuite.google.com/industries/healthcareHelena§Europe.https://qa.helena.careIntersysto§Europe.http://www.intersysto.euInTouch Health‡United States.https://intouchhealth.com/telehealth-solutionspMD‡United States.https://www.pmd.com/secure-messaging-telemedicineMicrosoft Teams/Skype for Business E3 and E5†Global.https://www.microsoft.com/en-us/microsoft-365/microsoft-teams/healthcare-solutionsSignal§Europe.ΔEncrypted, but not specifically a telehealth platform.https://signal.orgSilicon Practice FootFall∗United Kingdom.https://www.siliconpractice.co.uk/video-consultationsSpruce‡United States.https://www.sprucehealth.comTeleMedi§Europe.https://telemedi.beUpdox‡United States.https://www.updox.comUS Department of Veterans Affairs Video Connect‡United States.https://www.mobile.va.gov/app/va-video-connectVSee‡United States.https://vsee.comZoom for Healthcare†Global.https://zoom.us/healthcareProprietary EMR telehealth platformsVideo-conferencing platforms (not HIPAA- or PHI-secure)GoToMeetingSkypeZoomNon-public-facing mobile communication platforms (not HIPAA- or PHI-secure)Apple FaceTimeGoogle DuoGoogle HangoutsWhatsAppEMR = electronic medical record; HIPAA = Health Insurance Portability and Accountability Act; PHI = protected health information.∗ United Kingdom.† Global.‡ United States.§ Europe.¶ South America—Brazil.Δ Encrypted, but not specifically a telehealth platform. Open table in a new tab EMR = electronic medical record; HIPAA = Health Insurance Portability and Accountability Act; PHI = protected health information. Electrophysiology is well placed for virtual consultations. All preobtained data, including ECGs, ambulatory ECG monitoring, cardiac imaging, and coronary angiography can be adequately reviewed electronically. Digital tools such as direct-to-consumer mobile ECG (Table 2) and wireless blood pressure devices can be used to further complement the telehealth visit without in-person contact. CIED, wearable/mobile health, and clinical data can be integrated into the clinician workflow.Table 2Examples of remote ECG and heart rate monitoring devicesDeviceTypeCE markFDA clearanceAdditional features/notesWebsiteHandheld devicesAliveCor KardiaMobileWirelessYesYesFDA cleared for AF (1-lead) and for QTc (6L) for COVID-19 patients on HCQ ± AZMhttps://www.alivecor.com/kardiamobileBeurer ME 90Wireless1-lead ECGYesNohttps://www.beurer.com/web/gb/products/medical/ecg-and-pulse-oximeter/mobile-ecg-device/me-90-bluetooth.phpCardiac Designs ECG CheckWireless1-lead ECGYesYeshttps://www.cardiacdesigns.comCardioComm Solutions HeartCheck CardiBeat and ECG PenWireless1-lead ECGYesYeshttps://www.theheartcheck.comCOALAWireless1-lead ECGYesYesRemote lung auscultationhttps://www.coalalife.comEko DUOWireless1-lead ECGYesYesRemote cardiac auscultation/ phonocardiogramhttps://www.ekohealth.comOmron Blood Pressure + EKG MonitorWireless1-lead ECG + BP cuffNoYesUnited States and Canada onlyhttps://omronhealthcare.comEKGraphWireless1-lead ECGNoYesUnited Stateshttps://sonohealth.orgMobile cardiac telemetry devicesQardioQardioCoreChest strap1-lead ECGYesNoECG, HR, HRV, RR, activityhttps://www.getqardio.com/qardiocore-wearable-ecg-ekg-monitor-iphoneBardyDx CAMPatch1-lead ECGYesYesUnder clinical investigation for QTc monitoring in COVID-19 patientshttps://www.bardydx.comBioTel HeartPatch1-lead ECGYes—only for extended HolterYesFDA cleared for QTc monitoringhttps://www.myheartmonitor.com/device/mcot-patchBodyGuardian MINI Family/BodyGuardian MINI PLUSWirelessPatch: 1-lead ECG/Wired3-lead ECGYesYesECG, HR, HRV, RRhttps://www.preventicesolutions.com/hcp/body-guardian-mini-familyiRhythm Zio patch/Zio ATPatch1-lead ECGYesYeshttps://www.irhythmtech.comInfoBionic MoMe KardiaWired3-lead ECGYesYesRemote lung auscultationhttps://infobionic.comMediBioSenseMBS HealthStream, VitalPatch, MCTPatch1-lead ECGYesYesMonitors up to 8 vital signshttps://www.medibiosense.comMEMO PatchPatch/watch1-lead ECGNoNoAsia; Korea FDA approvedhttps://www.huinno.comMediLynx PocketECGWired3-lead ECGYesYesHRVhttps://www.pocketecg.comRhythMedix RhythmStarWired3-lead ECGNoYeshttps://www.rhythmedix.comSamsung S-patch CardioPatch1-lead ECGYesNoAsia; Korea FDA approvedhttps://www.samsungsds.com/global/en/solutions/off/cardio/cardio.htmlSmartwatchesApple Watch1-lead ECGYesYesFDA cleared for AF notificationhttps://www.apple.com/watchWithings Move ECG1-lead ECGYesNoRequires Health Mate app for ECG analysis/AF detectionhttps://www.withings.com/us/en/move-ecgAF = atrial fibrillation; AZM = azithromycin; BP = blood pressure; COVID-19 = coronavirus disease 2019; ECG = electrocardiogram; FDA = Food & Drug Administration; HCQ = hydroxychloroquine; HR = heart rate; HRV = heart rate variability; RR = respiratory rate. Open table in a new tab AF = atrial fibrillation; AZM = azithromycin; BP = blood pressure; COVID-19 = coronavirus disease 2019; ECG = electrocardiogram; FDA = Food & Drug Administration; HCQ = hydroxychloroquine; HR = heart rate; HRV = heart rate variability; RR = respiratory rate. Additional diagnostic information might be obtained without in-person contact using home enrollment of prescribed ambulatory rhythm monitors. Patch monitors can be mailed to patient homes and easily self-affixed, unlike Holter monitors with cables and electrodes requiring placement by health care workers. In some cases, new or follow-up telehealth visits will require an adjunctive in-person visit to perform a 12-lead ECG, ECG stress test, echocardiogram, or other diagnostic procedures. Occasionally, conventional clinic visits are required to accurately assess the impact of comorbidities or frailty on procedural risk, or to allow comfortable discussion with multiple family members when planning procedures with high risk. Telephone-only visits (ie, without video) may allow for a broader reach due to ease and ubiquitous accessibility as a communication strategy for immediate access for urgent matters. There are many barriers to implementation, such as inadequate reimbursement, licensing/regulatory and privacy issues, lack of infrastructure, resistance to change, lack of access/poor Internet coverage, restricted financial resources, and limited technical skills (eg, in the elderly patient population). Some telehealth and remote ECG monitoring technologies may be simply unaffordable and/or unavailable, leading to different levels of uptake within communities and across the globe. All stakeholders should collaborate to address these challenges and promote the safe and effective use of digital health during the current pandemic. In recent months, regulations have been eased to permit consults with new patients, issuing prescriptions, and obtaining consents. In that sense, the COVID-19 pandemic may serve as an opportunity to evolve current technologies into indispensable tools for our future cardiological practice. No specific cure exists for COVID-19.28Grein J. Ohmagari N. Shin D. et al.Compassionate use of remdesivir for patients with severe Covid-19.N Engl J Med. 2020; 382: 2327-2336Crossref PubMed Scopus (1957) Google Scholar, 29European Society of CardiologyESC guidance for the diagnosis and management of CV disease during the COVID-19 pandemic.https://www.escardio.org/Education/COVID-19-and-Cardiology/ESC-COVID-19-GuidanceGoogle Scholar, 30Chen Z. Hu J. Zhang Z. et al.Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial.medRxiv. 2020; (2003.2022.20040758. https://doi.org/10.1101/2020.03.22.20040758)Google Scholar Potential COVID-19 therapies, especially hydroxychloroquine and azithromycin, are being investigated in ongoing trials but also have been used off-label in many parts of the world. These may exert QT-prolonging effects31Haeusler I.L. Chan X.H.S. Guérin P.J. White N.J. The arrhythmogenic cardiotoxicity of the quinoline and structurally related antimalarial drugs: a systematic review.BMC Med. 2018; 16: 200Crossref PubMed Scopus (96) Google Scholar (Table 3) and, since recent observational data have questioned their efficacy, require a careful risk-benefit adjudication.32Geleris J. Sun Y. Platt J. et al.Observational study of hydroxychloroquine in hospitalized patients with Covid-19.N Engl J Med. 2020; 382: 2411-2418Crossref PubMed Scopus (1173) Google Scholar Combination therapy (eg, hydroxychloroquine and azithromycin) may have synergistic effects on QT prolongation.33Chorin E, Wadhwani L, Magnani S, et al. QT interval prolongation and torsade de pointes in patients with COVID-19 treated with hydroxychloroquine/azithromycin [published online ahead of print May 11, 2020]. Heart Rhythm. https://doi.org/10.1016/j.hrthm.2020.05.014.Google Scholar,34Saleh M. Gabriels J. Chang D. et al.Effect of chloroquine, hydroxychloroquine, and azithromycin on the corrected QT interval in patients with SARS-CoV-2 infection.Circ Arrhythm Electrophysiol. 2020; 13: e008662Crossref PubMed Scopus (234) Google Scholar In a retrospective cohort study of 1438 COVID-19 patients hospitalized in metropolitan New York (ie, a disease epicenter), cardiac arrest was more frequent in patients who received hydroxychloroquine with azithromycin than in patients who received neither drug.35Rosenberg E.S. Dufort E.M. Udo T. et al.Association of treatment with hydroxychloroquine or azithromycin with in-hospital mortality in patients with COVID-19 in New York state.JAMA. 2020; 323: 2493-2502Crossref PubMed Scopus (824) Google Scholar The adjusted hazard ratio for in-hospital mortality for treatment with hydroxychloroquine alone was 1.08, for azithromycin alone was 0.56, and for combined hydroxychloroquine and azithromycin was 1.35. However, none of these hazard ratios were statistically significant. The observational design of this study may limit interpretation of these findings. In the absence of clear efficacy data, treatment options should be individualized taking into account their proarrhythmic potential for torsade de pointes, which may be enhanced by concomitant administration of other QT-prolonging drugs (eg, antiarrhythmics, psychotropics, etc).Table 3Effect on QTc and proarrhythmia of experimental pharmacological therapies for COVID-1936CredibleMedsCOVID-19 experimental therapies and TdP risk.https://www.crediblemeds.org/blog/covid-19-experimental-therapies-and-tdp-riskGoogle ScholarQTc prolongationTdP riskChloroquine37Vicente J. Zusterzeel R. Johannesen L. et al.Assessment of multi-ion channel block in a phase I randomized study design: results of the CiPA phase I ECG biomarker validation study.Clin Pharmacol Ther. 2019; 105: 943-953Crossref PubMed Scopus (58) Google Scholar, 38Mzayek F. Deng H. Mather F.J. et al.Randomized dose-ranging controlled trial of AQ-13, a candidate antimalarial, and chloroquine in healthy volunteers.PLoS Clin Trials. 2007; 2: e6Crossref PubMed Scopus (116) Google Scholar, 39Wozniacka A. Cygankiewicz I. Chudzik M. Sysa-Jedrzejowska A. Wranicz J.K. The cardiac safety of chloroquine phosphate treatment in patients with systemic lupus erythematosus: the influence on arrhythmia, heart rate variability and repolarization parameters.Lupus. 2006; 15: 521-525Crossref PubMed Scopus (46) Google Scholar, 40Teixeira R.A. Martinelli Filho M. Benvenuti L.A. Costa R. Pedrosa A.A. Nishióka S.A. Cardiac damage from chronic use of chloroquine: a case report and review of the literature.Arq Bras Cardiol. 2002; 79: 85-88Crossref PubMed Scopus (35) Google ScholarModerate ↑Low risk of TdPHydroxychloroquine41McGhie T.K. Harvey P. Su J. Anderson N. Tomlinson G. Touma Z. Electrocardiogram abnormalities related to anti-malarials in systemic lupus erythematosus.Clin Exp Rheumatol. 2018; 36: 545-551PubMed Google ScholarModerate ↑Low risk of TdPAzithromycin42Zhang M. Xie M. Li S. et al.Electrophysiologic studies on the risks and potential mechanism underlying the proarrhythmic nature of azithromycin.Cardiovasc Toxicol. 2017; 17: 434-440Crossref PubMed Scopus (46) Google Scholar, 43Choi Y. Lim H.S. Chung D. Choi J.G. Yoon D. Risk evaluation of azithromycin-induced QT prolongation in real-world practice.Biomed Res Int. 2018; 2018: 1574806Crossref PubMed Scopus (74) Google Scholar, 44US Food and Drug AdministrationZITHROMAX (azithromycin) for IV infusion only. Highlights of prescribing information. Reference ID: 4051690.https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/050733s043lbl.pdfDate accessed: May 20, 2020Google Scholar, 45Ray W.A. Murray K.T. Hall K. Arbogast P.G. Stein C.M. Azithromycin and the risk of cardiovascular death.N Engl J Med. 2012; 366: 1881-1890Crossref PubMed Scopus (774) Google Scholar, 46Poluzzi E. Raschi E. Motola D. Moretti U. De Ponti F. Antimicrobials and the risk of torsades de pointes: the contribution from data mining of the US FDA Adverse Event Reporting System.Drug Saf. 2010; 33: 303-314Crossref PubMed Scopus (109) Google Scholar, 47Cheng Y.J. Nie X.Y. Chen X.M. et al.The role of macrolide antibiotics in increasing cardiovascular risk.J Am Coll Cardiol. 2015; 66: 2173-2184Crossref PubMed Scopus (117) Google Scholar, 48Maisch N.M. Kochupurackal J.G. Sin J. Azithromycin and the risk of cardiovascular complications.J Pharm Pract. 2014; 27: 496-500Crossref PubMed Scopus (28) Google ScholarModerate ↑Very low risk of TdPLopinavir/ritonavir37Vicente J. Zusterzeel R. Johannesen L. et al.Assessment of multi-ion channel block in a phase I randomized study design: results of the CiPA phase I ECG biomarker validation study.Clin Pharmacol Ther. 2019; 105: 943-953Crossref PubMed Scopus (58) Google ScholarModerate ↑Low risk of TdPTocilizumab49Grange S. Schmitt C. Banken L. Kuhn B. Zhang X. Thorough QT/QTc study of tocilizumab after single-dose administration at therapeutic and supratherapeutic doses in healthy subjects.Int J Clin Pharmacol Ther. 2011; 49: 648-655Crossref PubMed Scopus (17) Google ScholarMild ↑ or ↓NRFingolimodMild ↑NRRemdesivirNRNRInterferon alfacon-1NRNRRibavirinNRNRMethylprednisoloneNRNRNR = not reported; TdP = torsade de pointes. Open table in a new tab NR = not reported; TdP = torsade de pointes. In COVID-19 patients receiving prior antiarrhythmic therapy, there should be a thorough consideration of risk vs benefit before initiating any QT-prolonging COVID-19 therapies, especially considering their unproven value. For instance, although some recent observational studies highlight adverse effects of hydroxychloroquine in treating this infectious disease, its use is likely to persist outside of randomized trials because of its affordability and global availability compared with, for example, remdesivir.35Rosenberg E.S. Dufort E.M. Udo T. et al.Association of treatment with hydroxychloroquine or azithromycin with in-hospital mortality in patients with COVID-19 in New York state.JAMA. 2020; 323: 2493-2502Crossref PubMed Scopus (824) Google Scholar If one of these drugs is judged to be critical, monitoring should be initiated. If life-threatening arrhythmias (VT/VF) occur, the benefit of antiarrhythmic drugs, notably amiodarone, outweighs the potential harm of hydroxychloroquine or other QT-prolonging drugs targeting COVID-19, and in these cases antiarrhythmic drugs should be prioritized and used as deemed necessary. Most importantly, all modifiable predisposing factors for QTc prolongation (electrolyte disturbances, drug-to-drug interaction) that may enhance arrhythmia susceptibility should be corrected, and the small subset of individuals with an underlying genetic predisposition such as congenital long QT syndrome (in whom QTc-prolonging medications are contraindicated) should be identified. Additionally, caution must be exercised in case of subclinical or manifest myocarditis that may increase the vulnerability to proarrhythmias associated with QT-prolonging drugs. If drugs that exert a QT-prolonging effect are to be initiated in an inpatient setting, a baseline 12-lead ECG should be acquired. Following review of the QTc, patients can be stratified into low-risk group (QTc of <500 ms or <550 ms in the setting of wide baseline QRS) or high-risk group (baseline QTc of ≥500 ms or ≥550 ms in the setting of wide baseline QRS, or patients who are started on combination therapies), guiding selection of telemetered vs nonmonitored beds.50Giudicessi J.R. Noseworthy P.A. Friedman P.A. Ackerman M.J. Urgent guidance for navigating and circumventing the QTc-prolonging and torsadogenic potential of possible pharmacotherapies for coronavirus disease 19 (COVID-19).Mayo Clin Proc. 2020; 95: 1213-1221Abstract Full Text Full Text PDF PubMed Scopus (298) Google Scholar Low-risk patients treated with QT-prolonging agents may be monitored using MCT (or another available wearable) with twice-a-day transmission of QTc measurements and any urgent alerts. High-risk patients would require more contin